Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Oltman

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Acta Virologica|June 27, 2002
Significance of anti-interferon-alpha2 and sICAM-1 activities in the sera of viral hepatitis B and C patients treated with human recombinant interferon-alpha2D Stancek, N Fuchsberger, M Oltman, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|July 31, 2019
Use of specific anti-Xa levels in acute kidney injury to transition patients from oral factor Xa inhibitors to i.v. heparin infusionSara Zochert, Kiara M Oltman, Brittany M Elgersma, et al.
Acta Virologica|June 8, 1999
Therapy-induced antibodies to interferon-alpha 2a recognise its receptor-binding siteH Liptáková, E Kontseková, P Kabát, et al.
Hepato-Gastroenterology|August 3, 1999
Pulmonary complications in patients with inflammatory bowel diseaseL Kuzela, A Vavrecka, M Prikazska, et al.
Vnitrni Lekarstvi|October 2, 2003
[Liver biopsy in Slovakia]L Skladaný, P Jarcuska, S Hrusovský, et al.
Journal of Viral Hepatitis|January 7, 2015
Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 2V Saraswat, S Norris, R J de Knegt, et al.
Journal of Viral Hepatitis|January 7, 2015
The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - volume 2A Hatzakis, V Chulanov, A C Gadano, et al.
Journal of Viral Hepatitis|January 7, 2015
Strategies to manage hepatitis C virus (HCV) infection disease burden - volume 2E Gane, D Kershenobich, C Seguin-Devaux, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Acta Virologica|June 27, 2002
Significance of anti-interferon-alpha2 and sICAM-1 activities in the sera of viral hepatitis B and C patients treated with human recombinant interferon-alpha2D Stancek, N Fuchsberger, M Oltman, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|July 31, 2019
Use of specific anti-Xa levels in acute kidney injury to transition patients from oral factor Xa inhibitors to i.v. heparin infusionSara Zochert, Kiara M Oltman, Brittany M Elgersma, et al.
Acta Virologica|June 8, 1999
Therapy-induced antibodies to interferon-alpha 2a recognise its receptor-binding siteH Liptáková, E Kontseková, P Kabát, et al.
Hepato-Gastroenterology|August 3, 1999
Pulmonary complications in patients with inflammatory bowel diseaseL Kuzela, A Vavrecka, M Prikazska, et al.
Vnitrni Lekarstvi|October 2, 2003
[Liver biopsy in Slovakia]L Skladaný, P Jarcuska, S Hrusovský, et al.
Journal of Viral Hepatitis|January 7, 2015
Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 2V Saraswat, S Norris, R J de Knegt, et al.
Journal of Viral Hepatitis|January 7, 2015
The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - volume 2A Hatzakis, V Chulanov, A C Gadano, et al.
Journal of Viral Hepatitis|January 7, 2015
Strategies to manage hepatitis C virus (HCV) infection disease burden - volume 2E Gane, D Kershenobich, C Seguin-Devaux, et al.
Pageof 2